The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer
Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBCG VaccineCarcinoma, Transitional CellFemaleFollow-Up StudiesGenotypeGlutathione TransferaseHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPolymorphism, GeneticPrognosisRisk FactorsSmokingSurvival RateUrinary Bladder NeoplasmsConceptsNon-muscle invasive bladder cancerGSTT1-positive genotypeInvasive bladder cancerPrimary non-muscle invasive bladder cancerBCG failureBladder cancerPredictive valueInduction therapyIndependent predictorsHigh riskBacillus Calmette-Guérin induction therapyNull genotypeMultivariate logistic regression analysisMultivariate logistic regression modelBCG induction therapyInduction BCG therapySingle induction courseDisease-free survivalGlutathione S-transferase muKaplan-Meier analysisHigh-risk groupKaplan-Meier estimatesEarly responseLogistic regression analysisGSTT1 null genotype
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply